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Abstract
Population-based birth cohorts on asthma and allergies increasingly provide new insights into the
development and natural history of the diseases. Over 130 birth cohorts focusing on asthma and
allergy have been initiated in the last 30 years. A NIAID (National Institute of Allergy and
Infectious Diseases), NHLBI (National Heart Lung and Blood Institute), MeDALL (Mechanisms
of the Development of Allergy, Framework Programme 7 of the European Commission) joint
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workshop was held in Bethesda, MD, USA September 11–12, 2012 with 3 objectives (1)
documenting the knowledge that asthma/allergy birth cohorts have provided, (2) identifying the
knowledge gaps and inconsistencies and (3) developing strategies for moving forward, including
potential new study designs and the harmonization of existing asthma birth cohort data. The
meeting was organized around the presentations of 5 distinct workgroups: (1) clinical phenotypes,
(2) risk factors, (3) immune development of asthma and allergy, (4) pulmonary development and
(5) harmonization of existing birth cohorts. This manuscript presents the workgroup reports and
provides web links (AsthmaBirthCohorts.niaid.nih.gov or www.medall-fp7.eu) where the reader
will find tables describing the characteristics of the birth cohorts included in this report, type of
data collected at differing ages, and a selected bibliography provided by the participating birth
cohorts.
Keywords
Allergy; asthma; birth cohorts; NHLBI; NIAID; MeDALL
Introduction
Asthma and allergic diseases commonly appear during infancy and tend to persist until adult
life, thus birth cohort studies help to understand their determinants and evolution. Over 130
birth cohorts focusing on asthma and allergy have been initiated in the last 30 years 1,2,3 and
some have followed the participants for over 30 years.4,5
Work has begun to pool information across birth cohorts.3 To further improve our
understanding of existing asthma birth cohorts, an Asthma Birth Cohort Workshop was held
in Bethesda, MD, USA on September 11–12, 2012. The meeting was jointly sponsored by
the National Institute of Allergy and Infectious Disease (NIAID), and the National Heart,
Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH), and
MeDALL (Mechanisms of the Development of Allergy, FP7, European Commission). The
workshop allowed epidemiological, clinical and laboratory researchers conducting research
on asthma and other allergic diseases in birth cohorts, to meet to address a wide research
agenda. Representatives from major birth cohorts on asthma and allergies from North
America, Europe, Asia, and Australasia attended.
The workshop had the objectives of (1) documenting the knowledge that asthma/allergy
birth cohorts have provided, (2) identifying the knowledge gaps and inconsistencies and (3)
developing strategies for moving forward, including potential new study designs and the
harmonization of existing birth cohort data.
The meeting was organized around the presentations of 5 distinct workgroups, 4 of which
were charged with reviewing available birth cohort data and preparing a presentation of
results and knowledge gaps in pre-identified topics—asthma phenotypes, risk factors,
immune development, pulmonary development, while the 5th workgroup worked to identify
approaches for data pooling and harmonization (Table 1). Before the meeting, investigators
from birth cohorts in North America, Europe, Asia and Australasia were sent a questionnaire
to report their findings to date relevant to the workgroups (Table 2). The workgroups used
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this information along with extant literature and expertise as the basis for their reports. The
draft reports were presented and discussed at the meeting.
This article contains the final reports incorporating the input obtained from the meeting
attendees. Additional information gathered as part of the workshop is available at the NIAID
website (AsthmaBirthCohorts.niaid.nih.gov) and MeDALL website (www.medall-fp7.eu).
At these sites, the reader will find the characteristics of the birth cohorts included in this
report, types of data collected at differing ages, and a selected bibliography provided by the
participating birth cohorts. The database allows the user to search for data collected across
cohorts. The database will be updated as more cohorts are identified.
Workgroup 1: Clinical Phenotypes (group membership: Table 1)
Current definition and classification of childhood wheezing/asthma and allergic diseases
Birth cohort studies have been a highly productive source of knowledge about the
characteristics of asthma phenotypes in childhood because of their unique longitudinal
nature.
Studies in asthma have often used definitions developed by ISAAC6 and partly adopted by
European birth cohort collaborations GA2LEN7 and MeDALL8,9, in particular “physician
diagnosed asthma.” In some studies, definitions have combined symptoms and markers such
as lung function and airway hyper-responsiveness (AHR) to improve their validity.10
Commonly, symptoms were combined with IgE measurement to stratify allergic and non-
allergic subjects. Other approaches have included health care data using record linkage and
response to treatment (inhaled steroids) as a diagnostic criterion. Few cohorts have studied
asthma severity or other specific phenotypes like exercise induced-asthma, cough and
difficulty breathing. Most longitudinal studies in asthma have adopted the wheezing
phenotypes definitions described in the Tucson birth cohort (USA).11 The etiological
classification of wheezing (episodic viral wheeze and multi-trigger wheeze12) has been less
often used. An alternative approach has used scoring systems like the Asthma Predictive
Index13 or qualitative categories (like definite, probable, and possible asthma).
For rhinitis, the term “allergic” is restricted to symptoms with demonstrable IgE
sensitization (skin tests and/or serum specific IgE). The term atopic dermatitis or atopic
eczema is reported in the majority of birth cohorts but definitions vary.
Unsupervised statistical techniques like latent class or cluster analyses were used to identify
and define asthma phenotypes.8,9,14 Using latent class analysis in ALSPAC (UK) and
PIAMA (NL), wheezing patterns were in agreement with the Tucson classification.11,15,16
MAAS (UK) used another unsupervised approach to describe multiple longitudinal patterns
of sensitization.17 This is an area of growing interest and many cohorts are part of
MeDALL,8,9 which is applying both hypothesis-driven and data-driven (unsupervised
techniques) to redefine the asthma and allergic phenotypes.9
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The contribution of birth cohort studies to understand asthma and allergy phenotypes
In the Tucson birth cohort, late onset and persistent wheezing, together with AHR and low
airway function during childhood, are predictors of new asthma in young adulthood.18
Reduced lung function at birth is associated with an increased risk of asthma by the age of
10 years and with a low respiratory function at the age of 22.19,20 Lung function patterns
have been studied in PIAF (Australia) but the lung function impairment in children with
transient wheeze was not replicated.21
MAS (Germany) failed to show that exposure to inhaled allergens was a causal determinant
of asthma22, a finding confirmed by other studies. However, in MAS, sensitization to
inhaled allergens and persistence of sensitization during childhood was associated with
persistence of wheezing at school age.23 MAS showed that children with non-allergic
wheezing are more likely to lose their symptoms and have normal lung function at
puberty.23 In MAS, allergic rhinitis in preschool children is a predictor for subsequent
wheezing onset.24 In CAPS (USA), children with atopic eczema were more likely to have a
history of food allergies, allergic rhinitis, and current wheeze.25 A substantial degree of
asthma, rhinitis and eczema comorbidity was observed in ECA (Norway) and BAMSE
(Sweden). 26,27
Pediatricians are frequently asked to predict the future course of wheezing and asthma in
individual subjects. However, prognosis in an individual patient is difficult.28 The asthma
predictive index13 is effective for groups of subjects and has been proposed for individual
subjects.29 In ECA, combining IgE to inhalant allergens and severity of airways obstruction
at 2 years was superior in predicting asthma at 10 years than either alone.30 However,
current prediction algorithms aiming to identify individual preschool children having asthma
at school age are still of modest diagnostic value.31
Unmet needs
There is no consistent evidence that clinical phenotypes correspond to genuine biological
entities that reflect specific interactions between genes and environment. These phenotypes
may reflect a continuum of states rather than discrete entities. Exploration of new
phenotypes eventually may result in a refined classification of phenotypes that more closely
reflects the relevant pathogenic mechanisms. The interplay among asthma, rhinitis and
eczema is still poorly understood. Current asthma phenotypes are not amenable to primary
prevention and their natural history cannot be reliably predicted. There is a need to consider
alternative research approaches including the use of unsupervised statistical techniques with
available data as well as integrative systems biology. Some initiatives like MeDALL8,9
combine both approaches.
Research priorities
Broadly, research priorities could be classified in 3 groups (Table 3):
1. Better characterization of phenotypes including (a) a unique agreed upon
classification of asthma that can be applied to research, diagnosis and treatment, (b)
a better understanding of the interplay between asthma and allergy, (c) how allergic
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phenotypes interrelate across the life cycle, and (d) if extreme phenotypes can be
defined. 8,9
2. Natural history and its determinants. There is a well-established relationship
between lung function impairment and chronic wheezing and asthma. However,
links to new onset and chronic asthma in adults and to COPD are of great interest
but need more data.32
Another relevant aspect concerns risk stratification and risk prediction as current
models lack sufficient accuracy to be of clinical use at the individual level.
3. Pathogenesis. Understanding the mechanisms of asthma and allergies from early
life to the elderly (across the life cycle) is an important requirement for a better
understanding of phenotypes and their natural history (i.e., expression, progression,
and remission). There is a close interaction between clinical and epidemiological
research.
Workgroup 2: Asthma Risk Factors (group membership: Table 1)
The contribution of birth cohort studies to understand risk and protective factors
Numerous environmental determinants have been assessed in birth cohorts: exposure to
environmental tobacco smoke, ambient air pollution, and indoor factors such as household
chemicals, molds, and water damage. Environment plays a role during pregnancy and across
the life cycle.33 Early animal exposure, such as keeping a dog may be protective,34–36 but a
meta-analysis37 showed overall no protection with pet exposure. Consistent protective
associations were reported for growing up in a farming environment,35 while consistent
adverse associations were found for living in homes with visible molds.1 Some gene-
environment interactions have been detected. For example, in the Isle of Wight cohort (UK),
an interaction between maternal smoking during pregnancy and regions of the IL-13 gene
(SNP: rs20541) was reported in persistent childhood asthma.38 In CCAAPS (USA), an
association between traffic exposure and persistent wheezing during childhood was
modified by endotoxin exposure.39
Lifestyle has been studied in many cohorts such as day care, parental smoking, parental
stress, and psychosocial factors; dietary factors such as maternal allergen intake, vitamin D
and antioxidant ingestion in pregnancy, breastfeeding, hydrolysed formula feeding, bottle-
feeding in bed, introduction of solids and fish intake, introduction of probiotics and obesity.
In ACCESS, independent effects of prenatal and postnatal maternal stress on repeated
wheeze risk were found in children followed to age 2 years.40 In the Viva cohort (USA), a
greater risk for recurrent wheeze at age 2–3 years was predicted by lower birth weight,
greater increase in weight-for-length in the first 6 months of life, and adiposity.41 In the
combined GINIplus and LISAplus cohorts (Germany), rapid weight gain velocity was
associated with an increased risk for asthma until age of 10.42 This finding was replicated
using data from 8 European birth cohorts.43
Viral or bacterial diseases and infections may be a risk or a protective factor for developing
wheeze, asthma, and allergic diseases.44 Particular attention has been given to respiratory
syncytial virus (RSV) and human rhinovirus (HRV) infections. In COAST (USA), HRV
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wheezing in the first 3 yrs of life was a highly significant risk factor for the development of
asthma45, and this risk was significantly increased based on genetic variation at the 17q21
locus.46 Allergic sensitization further enhanced this risk,45 but interestingly, this increase in
risk was independent of genetic variation at the 17q21 locus. Endotoxin may be a biomarker
for complex microbial exposures. High home endotoxin levels protect against allergic
sensitization in farm and urban settings, whereas, in urban settings (EHAAS, USA)
endotoxin increased early wheeze risk.47,48 The microbiome in the gastrointestinal tract, the
respiratory tract, the skin and the environment has received much attention, but data from
cohort studies are very few and mostly relate to the gut microbiome and the development of
atopic dermatitis. 49–52
Unmet needs
The prospective design of birth cohort studies allows the investigation of the temporal
relation between environmental exposures and the new onset of disease. Exposures
occurring before the inception of disease suggest causal factors. The translation of these
findings to primary and secondary prevention is a major goal and future studies should focus
and interrogate factors that are promising and amenable to prevention and intervention trials.
Birth cohort studies can ideally inform later trials by:
• Investigating the relevant time windows of exposures through repeated
measurements starting in pregnancy,
• Assessing the individual and cumulative dose of exposures at these repeated time
periods, and
• Assessing the relevance and importance of various covariates and context
dependency (race, ethnicity, geography, age) of any observed risk and protective
exposures.
Research priorities
1. Birth cohort studies that include biological measures can investigate responses to
environmental exposures (e.g. immune responses, gene-environment interactions).
Such inbuilt mechanistic aspects will help understand whether risk and protection is
limited to particular subpopulations that might need to be targeted in subsequent
intervention trials.
2. In future and current (CHILD, WHEALS) studies, the new technologies for
exposure assessment such as high throughput techniques for microbial exposures
on body surfaces and the environment, and the intrinsic ‘omics’ determinants, will
create large and complex data sets of interrelated measures of exposure
(‘exposome’) and intrinsic determinants of disease (genome, metagenome,
transcriptome, etc.).
3. Novel statistical analytical techniques such as unsupervised approaches and
systems biology must be developed and applied to the vast amount of collected
data.
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Workgroup 3: Immune development (group membership: Table 1)
The contribution of birth cohort studies to understand immune development
Immune responses at birth are related to risk factors for developing wheezing, asthma, lower
respiratory tract infection, allergic sensitization and atopic dermatitis in infancy. Even so,
reconciling birth cohort findings is hindered by the complexity involved in immunologic
predictors, their measurement, developmental changes, and uncertainties in outcomes
definitions such as wheezing and asthma phenotypes, and differences in methodology
among investigators. Distinct immunologic patterns are associated with different outcomes
previously considered collectively under the umbrella of atopy.53 This complexity, along
with technical limitations in the standardization of assays, has presented a major challenge
to understanding the relationship between immune development and asthma.
A bias towards Th2 responses at birth is consistently associated with subsequent IgE
sensitization and wheezing. The purported Th2 bias may be better described as generally
low mononuclear cell responses to mitogens and allergens, with a more pronounced
reduction in interferon-gamma (IFN-γ) responses. After birth, children with recurrent
wheezing may develop enhanced Th1 responses, while the Th2 responses remain a risk
factor for asthma. Accordingly, early sensitization to allergenic proteins indicates increased
risk of wheezing and asthma.54 This relationship is not dichotomous and is influenced by
quantitative and qualitative measurements of allergic sensitization.17
Early patterns of immune development and allergic sensitization influence the subsequent
risk for wheezing and asthma.55 Prenatal and early postnatal factors modify early immune
development. These include, but are not limited to, family history, race, season of birth,
maternal smoking, mode of delivery, size at birth, diet, bioactive environmental exposures,
and day care.56,57 Studies in animal models and in infants and children suggest that
microbial effects may act on innate immunity and/or metabolic pathways and subsequent
sensitization to allergens, airway responses to infections, and eventual asthma.
Environmental factors influence the epithelium and innate immune elements to modify
adaptive immunity and these mechanisms appear to be relevant to the development of
airway inflammation and asthma.58
Unmet Needs
A number of technologic advances would facilitate future research efforts not only for the
research in immune development of asthma and allergy.
• Many assays of innate and adaptive immune responses are potentially useful, but
require optimization and standardization. Examples include generalized measures
of cellular responses to innate and adaptive stimuli, and especially assays providing
information about cell-specific responses. For example, tetramer technology could
enable tracking of T cell responses in an organ specific manner.59 Standardized
protocols, quality control checks, and pools of standardized reagents are necessary
first steps.
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• Comprehensive systems biology approaches60 offer the promise of providing
unbiased insights into biologic networks associated with asthma.61 Examples
include measurements of the lung and gut microbiome, gene coexpression
networks, epigenetic changes, metabolomic approaches focusing on airway-derived
fluids, and protein and epitope mapping of allergen-specific IgE and IgG responses.
Data from studies utilizing these technologies are needed to gain a holistic
understanding of environmental effects on immune development and the
development of asthma.
• New technologies are needed to provide information about lung immunity and
asthma.62 Do upper airway responses, which are easily accessible, provide an
informative model of immune changes in the lung in early life? Identification of
new biomarkers that reflect lung immune development and airway inflammation is
an important research objective.
• Development of integrative statistical methodology is needed for datasets that are
complex, voluminous, and contain both immune measurements and a host of
clinical data. Statistical methods are needed to account for repeat sampling, time
and age effects, and to distill huge datasets from systems approaches into
conceptual advances that can be translated into novel therapeutic targets.
Observational studies and systems biology approaches can generate reams of data,
but lack of appropriate high-throughput data processing methodology represents a
considerable bottleneck to progress.
Research priorities
Three specific areas of investigation relate to this central theme.
1- In-depth studies on the postnatal maturation of systemic adaptive and innate immune
function during early life are required, incorporating (where feasible) both systems-level and
epigenetic analyses. These studies should include the functions of a range of “orphan” cell
populations that have received limited attention in previous birth cohort studies. These
include, but are not restricted to, neutrophils, cytolytic T-cells, NK cells, dendritic cells and
TREC-positive recent thymic emigrants that dominate the circulating neonatal T-cell
compartment. Studies should specifically analyze the maturation of respiratory mucosal
immune function, exemplified by secretory IgA responses in saliva and nasal washes. Both
systemic and local immunity in the airways should be broadened to encompass situations in
which the steady state is perturbed by environmental challenges known to be associated with
asthma risk, typified by respiratory viral infections.
2- Studies focusing on bidirectional interactions between the microbiome and the host in
relation to immune maturation and asthma63 should be at a holistic level and encompass the
three major tissue compartments: gastrointestinal tract, respiratory tract and skin. The key
questions relate to colonization effects (qualitative/quantitative/kinetic) on metabolic
pathways and immunological and clinical outcomes, identification of specific bacteria
within complex exposures that are associated with beneficial effects, modulation of acute
viral respiratory infections on host immune responses, modulatory effects of host immune
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responses on microbiome components at baseline and during episodic airways inflammation,
and on the subsequent development and progression of asthma and related phenotypes.
3- Major underlying effects of gender on asthma risk may be mediated partly by sex-related
differences in immune maturation that are poorly characterized. These effects may manifest
throughout childhood, before, during and after puberty. Additional studies on gender
specific immune development are needed.
Workgroup 4: Pulmonary Development (group membership: Table 1)
Contribution of birth cohort studies to understand the impact of early lung function for
later allergic diseases
Low lung function in early life is associated with low function in adulthood, an increased
risk of wheeze in infancy and preschool children, and an increased risk of asthma in
childhood.20,21,64–66 Male gender and maternal smoking during pregnancy increase the
risks.
Reduced peak flow values have been found already in pre-school children exposed to high
traffic related air pollution, supporting findings in later childhood.67
The most predictive pulmonary function measurements are those that assess expiratory flow
at a given lung volume. Increased AHR in infancy is associated with adverse respiratory
outcomes in early childhood, but this association may decline with increasing age.64,68
Methodology to assess early pulmonary function in birth cohorts
Methods depend on the research question, ethical issues, anticipated cohort size, and
resources available, as some of the most informative tests are more expensive to perform,
require special expertise and sometimes sedation, and commercial equipment is not always
available.
• The raised volume forced expiration technique provides the most reproducible
and useful information on airway and pulmonary function.69,70 Its comparability to
forced expiration measurements used later in childhood allows better longitudinal
comparisons. However, it usually requires the infant to be asleep with sedation and
ethics committees often require a paediatrician to be present. Further studies are
needed to determine if the values early in life are influenced by increased airway
tone or are secondary to smaller-sized airway lumen or lower pulmonary elastic
recoil.
• The tidal forced expiratory flow technique71 predicts respiratory outcomes in
several long-term studies,20 and is easier to perform than raised volume forced
expiration.
• Tidal breathing flow pattern assessments have the advantage of being quicker to
perform, do not require sedation and can be performed in awake as well as sleeping
babies. Tidal breathing techniques would appear to be more subject to variation in
breathing patterns unrelated to underlying airway and lung structure, but in
practice, results derived can provide similar future associations19 to those of forced
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expiration. The ratios derived from tidal breathing patterns predict respiratory
outcomes.19
• Airway responsiveness assessments are more time consuming to perform than
baseline respiratory function tests. Inhalation challenge using histamine and
methacholine in early life can predict respiratory outcomes in childhood,64,68 but
the physiological mechanisms that contribute to AHR or the relationships with
future outcomes are unknown. Given the difficulties in matching agonist dose for
the size of the subject, comparisons between subjects of very different sizes are
best avoided, although for cohorts reviewed at specific ages, valid longitudinal
comparisons can be made by evaluating ranked data.21
• Responses to β-2 adrenergic agonists have not been performed in neonatal cohort
studies. In older infants, increased bronchial tone can be present prior to any
wheeze episodes,72 but bronchodilator response of infants with history of wheeze
has been inconsistently associated with asthma risk.73,74
• Forced oscillation technique (FOT) is useful in preschool children and can be
performed with minimal cooperation, but is less applicable in children less than two
years of age. When performed in birth cohort studies, reported results are
comparable to those obtained by spirometry.75,76
• Lung clearance index (LCI) providing information on ventilation inhomogeneity
in the lung can be assessed using the multiple breath inert gas washout technique
with tidal breathing. LCI has been used to detect airway disease in infants with
cystic fibrosis.77,78 LCI is being evaluated in a neonatal cohort study of asthma but
results are not yet available. However, LCI may be more useful as a marker of
disease than of airway or lung development.
Methodology to assess other related outcomes in birth cohorts
• Fractional exhaled nitric oxide (FeNO) has been assessed in many birth cohorts.
While there have been some relationships to wheezing early in life,79,80 levels may
be more related to IgE sensitization than asthma.81 In addition, the on-line and off-
line measurements used in infants may not adequately approximate the
standardized technique used in older cooperative subjects,82,83
• Lung imaging has rapidly advanced in recent years. High resolution computerised
tomography (HRCT) scans produce excellent resolution with substantially lower
radiation exposures and scanning times short enough to avoid general
anaesthesia.84 Magnetic resonance imaging (MRI) can assess lung growth and
development in utero, as well as extra utero without ionizing radiation.85,86 Further
development of both HRCT and MRI may allow pulmonary assessment early in
life for birth cohort studies. However, imaging neonates during tidal breathing are
limited to only the first few airway generations where quantitative measurements of
airway size and wall thickness can be obtained, and ideally, lung volume will need
to be standardized using the augmented-breath hold technique, which requires
sedation.87,88
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Unmet needs
• There is a need for the development of additional physiologic and imaging
techniques to assess infants without sedation and with minimal or without ionizing
radiation.
• There is a need to integrate respiratory functional and structural assessment with
immunologic, cellular, molecular, and genetic information.
Research priorities
1. Pre-morbid pulmonary dysfunction occurs very early in life and is associated with
asthma symptoms in childhood; however, trajectories and physiologic mechanisms
for different phenotypes are not well understood.
2. Pulmonary function assessments should be done as part of future birth cohort
studies whenever possible, since the contribution of initial pulmonary function to
asthma-related outcomes is needed when evaluating other risk factors.
3. Systems biology studies using assessments of molecular and cellular biology,
genetics, proteomics, immunological responses and microbiome are needed to
elucidate the mechanisms that affect pulmonary development.
Workgroup 5: Networking and Harmonization (group membership: Table 1)
Needs for harmonized birth cohorts
Over 130 birth cohorts with data on asthma and allergy have been initiated in the world over
the past 30 years. The timing of the establishment of these cohorts is critical as they span the
time period of a dramatic increase in these diseases. The information gathered is remarkable,
but data are in isolated, independent databases. Although the assessment methods of the
studies vary, most cohorts were established and followed using rigorous methodology and
data are usually available in electronic format. Most cohorts will follow children up to
adulthood. Since 2004, several research initiatives funded under the EU FP6-FP7 have
attempted to identify, compare and evaluate pooling data from existing European birth
cohorts (GA2LEN,7,89–90 ENRIECO,1,2 CHICOS2 and MeDALL8,9). The growing
networking capacity of birth cohort studies needs to be expanded to other countries, made
sustainable, and the cumulative learning of successive projects facilitated.3 Further, as old
cohorts continue follow up and new cohorts are developed, it would be optimal to collect
data in a standardized fashion that would allow either comparison or the harmonization of
essential core elements. Several reasons favour harmonization of existent questionnaires and
the pooling of established and future birth cohorts (Table 4).
Definition of the term “birth cohort”
Epidemiologists use the term “cohort” to describe a group of persons who are observed over
a period of time, commonly multiple years. An observational “cohort study” is an
epidemiologic study of individuals who are exposed in different degrees (or not exposed at
all) to a risk or protective factor hypothesized to influence the occurrence of a given disease
or outcome. Terms such as follow-up, longitudinal, and prospective study, describe essential
features of an observational cohort study.91
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The term “birth cohort study” is generally used to describe a cohort study where study
subjects (newborns, infants) were recruited shortly after birth (sometimes mothers were
approached already during pregnancy) and observed over many years to examine
associations between early life exposures and childhood outcomes.
The term “interventional” birth cohort study has been used occasionally. It refers to
investigations where newborns (often at high-risk e.g. from allergic parents) were recruited
for evaluating the efficacy of a preventive measure. Many epidemiologists would not
describe such an approach as a cohort study (not purely observational anymore) but rather as
an intervention study. This type of study is an experiment, e.g. a randomized or non-
randomized controlled trial, in which subjects are allocated into groups, to evaluate the
efficacy and safety of a preventive or therapeutic regimen.91 Such studies have also been
used to evaluate etiological factors for allergic disorders. However, direct pooling of data
from observational and interventional studies is not advisable, as inclusion and exclusion
criteria and protocols from such studies usually differ considerably. Furthermore,
interventions, even placebo, may have influenced the occurrence of disease, making it
difficult to properly evaluate associations between exposures and occurrence of these
diseases. Depending on the specific research question, however, separate pooling of data
from either observational or intervention studies may be desirable and operating definitions
can be discussed during harmonization meetings.
Systematic review on birth cohorts
A systematic review aimed to identify, appraise, select and report all high quality evidence
concerning birth cohorts in allergy and asthma was initiated around the world using an
exhaustive summary of literature.
How harmonization of birth cohorts can be done?
The complexity and work load of harmonizing research protocols and databases, in part or in
total, needs to be addressed with a well-planned agenda of long-term initiatives and
investigator and programming resources. The numerous institutional and ethical issues
underlying large networked studies should be identified and addressed. These challenges are
complex, demanding and require research strategies to reduce fragmentation and facilitate
the incorporation of lessons learned from studies so they are effectively passed into the next
ones.2 MeDALL has started to harmonize 123 clinical questions and a workshop was held in
Barcelona November 6–9, 2012 to finalize the process.
Uniform core questionnaire for birth cohorts on asthma and allergy
MeDALL (www.medall-fp7.eu) has developed a uniform questionnaire translated in 6
languages and available online. This questionnaire is interoperable with the harmonized
questions so that historical and newly collected data may be compared.92
Research priorities
The discussion during the workshop showed the difficulties that can be encountered in
pooling existing data. In particular, funding and ethical issues were clearly identified.
Workshop participants indicated that ethical issues must be carefully considered and there
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needs to be an Ethics Work Package as well as an Ethics Advisory Board in the project.
Another important aspect was the trust of the different cohort PIs to release data to other
investigators. This has also been taken into account in GA2LEN and further expanded in
MeDALL to preserve privacy of data.
On the other hand, the importance of pooling data in order to better answer etiological
questions was recognized, as well as the possibility of developing a uniform questionnaire
which could be used in ongoing or new studies and could be linked with existing historic
data.
Conclusions
Existing population-based birth cohorts have contributed to our knowledge of the
development of asthma and atopy in many areas such as: (1) characterizing different
wheezing phenotypes, (2) documenting the differing onset of aeroallergen reactivity, (3)
describing the natural history of asthma and pulmonary functions, (4) noting the importance
of early life risk factors such as lower lung function or pre- and post-natal ETS exposure and
the later development of asthma, and (5) identifying gene-environment interactions such as
the RSV 17q21.
Collaboration across population-based asthma birth cohorts can provide information when
findings from individual cohorts are inconclusive or contradictory. Harmonization across
existing and newly created birth cohorts will facilitate these types of analyses. A number of
collaborative efforts involving multiple birth cohorts have already occurred. The topics have
included pet ownership,37 maternal smoking in pregnancy,93 and mold and dampness,1 and
the link between weight gain and asthma.43 These efforts demonstrate how collaboration
across cohorts can provide adequate sample sizes to answer research questions. The
availability of the publically accessible dataset (AsthmaBirthCohorts.niaid.nih.gov and
www.medall-fp7.eu) that was developed as part of this workshop will provide researchers
with information to establish future research collaborations.
New birth cohorts will be needed to apply new technologies to current research interests, to
provide data on new research interests and the impact of ongoing societal changes. The
MeDALL allergen-chip, which can evaluate the IgE and IgG reactive profiles of more than
170 allergen molecules, is now available to more completely characterize the allergic status
of an individual.94 New technologies are now available to more accurately and completely
characterize the microbiome. However, stored samples from existing cohorts will not be
sufficient to fully investigate this issue. Exposure to a Western lifestyle has been an area of
considerable interest in asthma and allergy. A number of countries around the world (e.g. in
Eastern Europe and Asia) are in transition to a more Western style of life. Birth cohorts in
these countries could help us better understand how these changes will impact future asthma
and allergy rates.
The five workgroups have identified many areas of future research interest. Establishing
criteria for asthma phenotypes that are mechanistically-based and reflect biological entities,
including degrees of severity, are the highest priority. Other research priorities include
Bousquet et al. Page 14
J Allergy Clin Immunol. Author manuscript; available in PMC 2015 June 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
investigations to define the natural history and determinants of disease and underlying
mechanisms of the various asthma phenotypes. Incorporation of pulmonary function and\or
structure measurements and measurements of immune development are strongly encouraged
in all birth cohorts. Further technical development will be necessary to make this possible.
Innovative statistical approaches such as systems biology approaches should be utilized for
analysis of complex datasets created by cohort studies. Efforts to harmonize data of the
different cohorts are just beginning, and appear to be important steps towards understanding
similarities and differences related to exposures, outcomes and phenotypes around the
world. The panel concluded that a combination of investigator leaders and novel ideas is
required to move forward towards achieving these goals and objectives. Future directions
include expanding the reach of existing cohorts into other chronic diseases as the
participants age. A follow up meeting on this topic was held in Montpellier, France in
December, 2013.
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Table 1
Participants in Workgroups
Clinical Phenotypes Workgroup Asthma Risk Factors
Chair: Fernando D. Martinez, M.D.
Co-Chair: Josep M. Anto, M.D., Ph.D.
Members:
J. Henderson, M.D.
Allan Becker, M.D.
Joachim Heinrich, Ph.D., M.Sc.
Robert Wood, M.D.
D. Bernstein, M.D.
Dennis R. Ownby, M.D.
Chair: Erika R.M. von Mutius, M.D., M.Sc.
Co-Chair: Robert F. Lemanske Jr., M.D.
Members:
S. Hasan Arshad, D.M.
Diane R. Gold, M.D., M.P.H.
Kathleen Belanger, Ph.D.
Malcolm R. Sears, M.B., Ch.B.
Angela Simpson, M.D., Ph.D.
Xiaobin Wang, M.D., M.P.H., Sc.D.
Kecia N. Carroll, M.D., M.P.H.
Philip J. Cooper, Ph.D.
Anita Kozyrskyj, Ph.D.
Immune Development Pulmonary Development
Chair: James E. Gern, M.D.
Co-Chair: Patrick G. Holt, Sc.D.
Members:
Anne L. Wright, Ph.D.
Rudy Valenta, M.D.
Dan J. Jackson, M.D.
Mario Castro, M.D., M.P.H.
Rachel L. Miller, M.D.
Len B. Bacharier, M.D.
Chair: Robert Tepper, M.D., Ph.D.
Co-Chair: Peter N. Le Souef, M.D.
Members:
Rosalind J. Wright, M.D., M.P.H.
Scott T. Weiss, M.D., M.S.
Padmaja Subbarao, M.D., M.Sc.
Karin Lodrup-Carlsen, M.D., Ph.D.
Wayne J. Morgan, M.D.
Networking and Harmonization On paper but not on working group
Chair: Jean J. Bousquet, M.D.
Co-Chair: Christine Cole Johnson, Ph.D.
Members:
Thomas Keil, M.D., M.Sc.
Matthew Gillman, M.D., S.M.
Michael Cabana, M.D., M.P.H.
Patrick Ryan, Ph.D.
Soo-Jong Hong, M.D., Ph.D.
Debra Stern, M.S.
Anna Bergstrom, Ph.D.
Isabelle Momas, Ph.D. – non attendee
H.A. (Jet) Smit, Ph.D.
Mariona Pinart, Ph.D.
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Table 2
Request for Information sent to Birth Cohorts Prior to the meeting
Clinical Phenotypes Workgroup
1 Which are the main asthma phenotypes you have identified in your birth cohort? Please provide a definition of these phenotypes.
2 Which are the more relevant new findings you have published so far about the asthma phenotypes in your cohort? Please mention
up to 5 (each) about these phenotypes/risk factors.
3 Has your birth cohort contributed to any relevant methodological development in regards to phenotypes? Please specify.
4 Which are the main priority areas for future research in birth cohorts regarding asthma phenotypes?
Asthma Risk Factors Workgroup
1 Which are the more relevant new findings you have published so far about the risk factors for asthma in your cohort? Please
mention up to 5 (each) about these risk factors.
2 Has your birth cohort contributed to any relevant methodological development in regards to risk factors? Please specify.
3 Which are the main priority areas for future research in birth cohorts regarding asthma risk factors?
Immune Development Workgroup
1 Which are the main immunologic outcomes you have measured in your birth cohort and at what ages?
2 Which are the more relevant new findings you have published so far about immune development in your cohort? Please mention
relationships to wheezing, asthma, and allergic sensitization.
3 Has your birth cohort contributed to any relevant methodological development for immune assessments? Please specify.
4 Which are the main priority areas for future research in birth cohorts regarding immune development and asthma? Include
suggestions related to technologic advances and study designs.
Pulmonary Development Workgroup
1 What pulmonary outcomes have you included in your birth cohort and at what ages?
2 Which are the more relevant new findings you have published so far about the pulmonary development in your cohort?
3 Has your birth cohort contributed to any relevant methodological development in regards to pulmonary development? Please
specify.
4 Which are the main priority areas for future research in birth cohorts regarding pulmonary development?
Networking and Harmonization Workgroup
1 Harmonization efforts to date (current MeDALL focus on Phenotypes)
2 Future harmonization efforts
3 Develop a harmonized questionnaire for the comparability of existing birth cohort studies
J Allergy Clin Immunol. Author manuscript; available in PMC 2015 June 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Bousquet et al. Page 24
Table 3
Research priorities of clinical phenotypes
Better characterization of clinical phenotypes
 Allergic vs non allergic phenotypes
 Comorbidity of allergic phenotypes
 Unsupervised phenotyping (using cluster, LCA and other methods)
 Environmental induced phenotypes (air pollution, low chemical dose, etc.)
 Risk factors of severity and difficult to treat wheezing
 Stratified medicine approach in asthma
 Evolution & validation of new of phenotypes
 Gender, race and genetics as phenotypical determinants
 Computational models for complex data/multifactorial assessment of risk factors
Natural history and its determinants
 Long term patterns of airflow limitation from early life to late adulthood and COPD
 Role of lung function in assessing the phenotypes
 Risk prediction and severity scores
 Natural history (puberty, gender, race/ethnicity, minorities, etc.)
 Influence of antenatal and in utero risk factors on phenotypes
Mechanisms of asthma and allergies
 Genomic (genes and epigenetics) determinants
 Overweight, obesity, growth, fat distribution and related mechanisms
 Biomarkers
 Immunological mechanisms and immunophenotyping
 Vitamin D
 Gut microbiome
 Stress and neurophenotyping
 Microbiome and its interactions with immunological mechanisms
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Table 4
Reasons favouring harmonization of existent questionnaires and the pooling of established and future birth
cohorts
• Improving the assessment of the consistency of findings across various populations and facilitating research explaining
heterogeneous results from analyses of individual cohorts
• Achieving the statistical power needed to assess both genetic and environmental determinants and their interactions
• Assessing the life course of subgroups of allergic and asthmatic phenotypes including economic burden and quality of life
associated with rare but very severe phenotypes
• Determining gender-specific differences across different cultures and regions
• Broadening the diversity of environmental exposures as represented in different geographic settings (dietary, inhalant, socio-
economic factors)
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